Please assess the completion status of the following clinical trial:

Trial Title: Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \<48 hours of age,~* 30 - 36 weeks gestational age at birth based on best estimate using obstetrical sonography (first or second trimester), solid dating criteria, or Ballard examination,~* Birth weight of ≥ 1,000 g,~* 5 minute Apgar score ≥5,~* Requiring nasal cannula O2 \> 1 liter per minute (LPM), continuous positive pressure (CPAP), or non invasive positive pressure ventilation (NIPPV) for treatment of respiratory failure,~* Requiring a fraction of inspired oxygen (FIO2) of at least 0.25 to maintain arterial oxygen saturation (SaO2) 88-94%,~* Parent or guardian has signed informed consent and agrees to all study- related procedures, including those required after hospital discharge.~Exclusion Criteria:~* Major congenital anomaly~* Intubation and surfactant in the delivery room or prior to enrollment in the Neonatal Intensive Care Unit (NICU). Excludes intubation for suctioning.~* Known congenital infection (bacterial, viral),~* Perinatal asphyxia (5 minute Apgar \<5, umbilical artery pH \< 7.0 or evidence of neonatal encephalopathy),~* Mother and/or infant is enrolled in another clinical trial (excluding observational) or has received an investigational drug,~* Has undergone or is anticipated to require a major surgical procedure within the first 48 h of life,~* Any condition which could preclude receiving study drug or performing any study-related procedures,~* Use of postnatal corticosteroids,~* Parent or guardian is unable or unwilling to complete study procedures after hospital discharge.

- Gender: ALL
- Minimum Age: 30 Weeks
- Maximum Age: 36 Weeks
- Healthy Volunteers: f

Study Arms:
- inhaled Nitric Oxide (Type: EXPERIMENTAL): iNO to start at 20 parts per million (ppm) for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.
- Nitrogen Gas (Type: PLACEBO_COMPARATOR): Placebo gas will be adjusted the same as study gas: to start at 20ppm for the first three days of life. The dose will then be decreased to 10 ppm for three days, 5 ppm for 3 days and then 2 ppm until all high flow respiratory support has been discontinued.

Based on this trial design, predict the completion outcome and termination type (if applicable).